About BRD4 Inhibitor-27
MI-CP151 was a phase 1b randomised, double-blind, placebo controlled, dose-escalation, multicentre analyze To judge various intravenous doses of sifalimumab, in adult patients with dermatomyositis or polymyositis (NCT00533091). Major demo targets have been To judge the safety and tolerability of sifalimumab in dermatomyositis or polymyositis indivi